29 September 2021 | Wednesday | News
Image Source : Public Domain
Biocytogen announces a collaboration with Envigo, a global organization that offers the widest range of research models and related services. The two companies are committed to supporting the research applications of the triple-immunodeficient B-NDG mouse. Envigo is the exclusive supplier of B-NDG mice in the United States, Europe and some regions of Asia-Pacific.
The triple-immunodeficient B-NDG mouse model was independently designed and produced by Biocytogen. The B-NDG mice were created by suppressing the IL2rg gene from NOD-scid mice with severe immunodeficiency phenotype. Lacking mature T cells, B cells or functional NK cells, and presenting deficiencies in cytokine signaling, this mouse model is highly immunodeficient and able to withstand the transplantation of human immune cells. The model is widely used in research and drug discovery in many fields, such as oncology, immuno-oncology, infectious diseases, and stem cell biology.
Dr. Adrian Hardy,President and CEO of Envigo, commented: "Our collaboration with Biocytogen further expands the range of models available to Envigo customers. The B-NDG model, and future models that will follow, offer a robust alternative to existing immunodeficient models for critical research and development of life-saving therapies."
Dr. Yuelei Shen, President and CEO of Biocytogen, said: "Both companies are dedicated to providing good non-clinical models for basic research and drug development. We believe this collaboration, leveraging the high quality of mouse models generated by Biocytogen and Envigo's breeding facilities and health monitoring programs, can meet the needs in these related fields."